Results 91 to 100 of about 15,200 (191)

Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma

BMC Cancer
Background Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with direct on-tumor and immunomodulatory mechanisms of action. Daratumumab-based treatment is a standard of care for multiple myeloma (MM) based on data from randomized controlled
Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu   +17 more
doaj   +1 more source

Myeloma Treatment on SÄS – Does it conform to good national standard? [PDF]

, 2017
Myeloma Treatment on SÄS – Does it conform to good national standard? Stefan Carslöv Supervisor: Ulf-Henrik Mellqvist Department of Medicine, Södra Älvsborg Hospital, Borås, Sweden Introduction Myeloma has an incidence of approximately 600 patient per ...
Carslöv, Stefan
core  

Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry

American Journal of Hematology, Volume 101, Issue 2, Page 365-375, February 2026.
Jon Salmanton‐García, Francesco Marchesi, Milan Navrátil, Iker Falces‐Romero, Maria Ilaria Del Principe, Jorge Labrador, Klára Piukovics, Verena Petzer, Monika M. Biernat, Michail Samarkos, Dario Leotta, Nicola Fracchiolla, Anna Dąbrowska‐Iwanicka, Antonio Vena, Benjamín Víšek, Yavuz M. Bilgin, Jens Van Praet, Mario Virgilio Papa, Inmaculada Heras Fernando, Francesca Farina, Ľuboš Drgoňa, Josip Batinić, Barbora Weinbergerová, Nurettin Erben, Joanna Drozd‐Sokołowska, Patricia García‐Ramírez, Annarosa Cuccaro, Martin Čerňan, Nicola Sgherza, Tobias Lahmer, Donald C. Vinh, Gaëtan Plantefeve, Alberto López‐García, Chiara Cattaneo, Nikola Pantić, Sofya Khostelidi, Julio Dávila‐Valls, Andrés Soto‐Silva, László Imre Pinczés, Ferenc Magyari, Reham Abdelaziz Khedr, Michelina Dargenio, Martijn Bakker, Igor Stoma, Carolina Garcia‐Vidal, Ildefonso Espigado, Claudio Cerchione, Caterina Buquicchio, Zlate Stojanoski, Gabriele Magliano, Stefanie K. Gräfe, Avinash Aujayeb, Lucia Prezioso, Vladimir Otašević, Maria Merelli, Erica Mackenzie, Andreas Glenthøj, Eleni Gavriilaki, Noha Eisa, Mario Delia, Alessandro Busca, Ahlam Almasari, Tatjana Adžić‐Vukičević, Ivana Urošević, Uluhan Sili, Carolina Miranda‐Castillo, Gustavo‐Adolfo Méndez, Stef Meers, Monia Marchetti, Nicola Coppola, Gökçe Melis Çolak, Darko Antić, Ditte Stampe Hersby, Pellegrino Musto, Milche Cvetanoski, Martin Schönlein, Tommaso Francesco Aiello, Elena Arellano, Davide Nappi, Sonia Martín‐Pérez, Mirjana Mitrović, Raul Cordoba, Romane Prin, Marta Callejas‐Charavia, Gina Varricchio, Martina Bavastro, Alessandro Limongelli, Amalia N. Anastasopoulou, Alessandra Romano, Dominik Wolf, Kevin Nguyen, Lukas Van Den Ven, Alessia Di Pilla, Antonio Giordano, Oliver A. Cornely, Livio Pagano   +95 more
wiley   +1 more source

DARATUMUMAB: REVISÃO DA ATUAÇÃO E INTERFERÊNCIA NOS TESTES PRÉ- TRANSFUSIONAIS EM PACIENTES COM DIAGNOSTICO DE MIELOMA MÚLTIPLO

Hematology, Transfusion and Cell Therapy
Objetivo: Discutir a interferência da medicação Daratumumab nos testes pré-transfusionais em amostras de pacientes diagnosticados com Mieloma Múltiplo que necessitam de transfusões sanguíneas.
GN Leôncio
doaj   +1 more source

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma:CASSIOPEIA minimal residual disease results [PDF]

Previous results from CASSIOPEIA demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with ...
Borgsten, Fredrik, Broijl, Annemiek, Béné, Marie C., Cabarrou, Bastien, Caillot, Denis, Carson, Robin, Corre, Jill, de Boer, Carla, Dejoie, Thomas, Delforge, Michel, Facon, Thierry, Filleron, Thomas, Hebraud, Benjamin, Hua, Winnie, Hulin, Cyrille, Krevvata, Maria, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Mahéo, Sabrina, Moreau, Philippe, Perrot, Aurore, Rowe, Melissa, Sonneveld, Pieter, Tuozzo, Alba, van de Donk, Niels W.C.J., Vanquickelberghe, Véronique, Vincent, Laure, Wang, Jianping, Wuilleme, Soraya, Zweegman, Sonja   +30 more
core   +1 more source

Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions. [PDF]

, 2019
Despite the many prospective randomized trials that have been available in the past decade regarding the optimization of radiation, hormonal, and surgical therapies for high-risk prostate cancer (PCa), many questions remain.
Chen, Victor E., Den, Robert B., Greenberger, Benjamin A.   +2 more
core   +1 more source

Pretransfusion Testing and Daratumumab: Assessing Interference Risks and Developing Solutions

Global Journal of Transfusion Medicine
Daratumumab is a monoclonal antibody; anti-CD38 is used for the treatment of multiple myeloma and other hematological disorders. Daratumumab, binds to CD 38 on red blood cells (RBCs), interfering with pretransfusion testing. This interference can lead to
Saroj Rajput, Tathagata Chatterjee, Rahul Bhargava, Sanjay Rai   +3 more
doaj   +1 more source

Rapid identification of daratumumab interference with M-protein detection using MALDI-TOF mass spectrometry: a case study involving renal light chain amyloidosis

Practical Laboratory Medicine
Therapeutic monoclonal antibodies (t-mAbs), such as daratumumab (anti-CD38), are increasingly used in plasma cell disorders including systemic AL amyloidosis.
Hou-Long Luo, Anping Xu, Ling Ji
doaj   +1 more source

Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review [PDF]

This systematic review examines the available clinical data on CD34+ cell mobilization, collection, and engraftment in multiple myeloma patients treated with the anti-CD38 monoclonal antibodies daratumumab and isatuximab in clinical trials and in real ...
Barbato S., Bigi F., Cavo M., Iezza M., Mancuso K., Manzato E., Masci S., Pantani L., Puppi M., Restuccia R., Rizzello I., Sacchetti I., Sartor C., Tacchetti P., Talarico M., Zamagni E.   +15 more
core   +1 more source

Mechanisms of action and clinical development of elotuzumab [PDF]

, 2017
Colonna, Marco, Ritchie, David
core   +2 more sources